Effectiveness bank home page. Opens new window Subject search results

You have found 24 entries. Starting with the most recently added or updated entries, the list shows in orange the type of entry, year the original document was published (or if one of our own documents, the year last updated), and the type of file you will download when you click on the title. In blue is the document’s title followed by a brief description.

Click blue titles to view full text in a new window
Use the selectors at the bottom to turn to the next page in the list of documents
Re-order the list by the main topic addressed or by the most recently published documents


If you have not found what you want you could:
Tab back to the Subject search page/tab to amend your original search.
Try a new search (clears your previous selection).
Instead try a free text search for documents which contain the words you specify.
Or try browsing back issues of the magazine or recent bulletins.
Documents are regularly added. Use the e-mail update service to monitor additions.
Try the information services provided by partner agencies.
Tried everything? E-mail the Findings editor for help by clicking on this logo Drug and Alcohol Findings logo



DOCUMENT 2018 HTM file
Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families: Treatment Improvement Protocol: TIP 63

Expanding access to medication is an important public health strategy for tackling opioid use disorder, concludes US government agency guidelines. While some people stop using opioids without medication, many benefit from access to methadone, naltrexone, and buprenorphine for varying lengths of time, including lifelong treatment.

HOT TOPIC 2018 HTM file
Opiate-blocking implants: magic bullet or dangerous experiment?

‘Hot topics’ offer background and analysis on important issues which sometimes generate heated debate. Opinion is sharply divided on the ethics and effectiveness of long-acting implanted or injected opiate-blocking medications, products not approved for medical practice in the UK, but which some see as a major breakthroughs in overcoming addiction to heroin and allied drugs.

STUDY 2016 HTM file
Extended-release naltrexone to prevent opioid relapse in criminal justice offenders

Added to basic counselling alone, monthly injections of the opioid-blocking drug naltrexone helped prevent relapse among US offenders with a history of opioid dependence recently released from prison or under criminal justice supervision in the community – findings most applicable to those who prefer opioid-free to opioid-maintenance treatments.

MATRIX CELL 2018 HTM file
Drug Treatment Matrix cell B3: Practitioners; Medical treatment

Seminal and key research and reviews on the influence of the practitioner in the medical treatment of drug dependence. Investigates the how clinician-patient relationships might be affected by enforcing clinic rules and the potential importance of doctors forming a “whole person’ relationship with patients.

STUDY 2017 HTM file
Effectiveness of injectable extended-release naltrexone vs daily buprenorphine–naloxone for opioid dependence: A randomized clinical noninferiority trial

Can monthly injections of extended-release naltrexone be considered on a par with the standard daily opioid substitute in Norway for people wanting to maintain abstinence from heroin?

STUDY 2015 HTM file
Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial

Though few seemed willing to try this treatment, among those who did, opiate-blocking injections active for about a month helped formerly dependent prisoners in New York City’s jail avoid relapse to regular opiate use after release.

DOCUMENT 2015 HTM file
American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use

From the USA’s professional society for clinicians and allied professionals in the field of addiction medicine, comprehensive recommendations on how doctors can use medications to treat addiction to heroin and other opioids.

STUDY 2015 HTM file
Extended-release naltrexone for alcohol and opioid problems in Missouri parolees and probationers

Long-acting injectable naltrexone blocks the effects of opiates for about a month and has also helped dependent drinkers cut back. Treatment records in the US state of Missouri showed that among the few problem substance using offenders allocated to or who chose this treatment, a much higher proportion became abstinent than those offered other kinds of addiction treatment.

REVIEW 2010 HTM file
Long-acting depot formulations of naltrexone for heroin dependence: a review

Researcher responsible for a major Russian trial of long-acting naltrexone for the treatment of heroin dependence reviews the effectiveness and safety of this form of the drug and of another long-acting form implanted under the skin.

STUDY 2012 HTM file
Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial

Would dually addicted heroin and stimulant users fitted with an opiate-blocking naltrexone implant simply escalate their stimulant use? The issue is important because multi-drug use is the norm. In this Finnish-Russian study it was the reverse – amphetamine use decreased as well as heroin use.


Select search results page

NEXT 1 2 3